

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2025/188802 A8

(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(51) International Patent Classification:

A61K 31/502 (2006.01) *A61P 11/00* (2006.01)
A61B 6/50 (2024.01) *G16H 50/20* (2018.01)
A61K 31/444 (2006.01) *G16H 50/50* (2018.01)
A61K 31/497 (2006.01)

(72) Inventors: **DE LOS RIOS, Miguel**; 12547 Carnel Canyon Rd, San Diego, California 92130 (US). **HOOD, John**; 100 Stratford Court, Del Mar, California 92014 (US). **DIFRANCESCO, Anita J.**; 3773 Derby Bluffs Way, San Diego, California 92130 (US). **DELLAMARY, Luis A.**; 829 Quiet Hills Dr, San Marcos, California 92069 (US). **FROHNA, Paul A.**; 496 Santa Cecelia, Solana Beach, California 92075 (US).

(21) International Application Number:

PCT/US2025/018407

(22) International Filing Date:

04 March 2025 (04.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/561,444	05 March 2024 (05.03.2024)	US
63/649,067	17 May 2024 (17.05.2024)	US
63/711,648	24 October 2024 (24.10.2024)	US

(74) Agent: **HOWLAND, William C.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(71) Applicant: **ENDEAVOR BIOMEDICINES, INC.**
[US/US]; 12707 High Bluff Drive, Suite 300, San Diego, California 92130 (US).

(54) Title: METHODS OF IMPROVING LUNG FUNCTION




FIG. 2

(57) Abstract: The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib monotherapy as the main component to a subject in need thereof, as well as diagnostic criteria and markers establishing the progress of therapy.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

02 October 2025 (02.10.2025)

(15) Information about Correction:

see Notice of 02 October 2025 (02.10.2025)